Behavioral and neurochemical effects of sodium butyrate in an animal model of mania
Behavioral and neurochemical effects of sodium butyrate in an animal model of mania
复制标题
DOI：
10.1097/fbp.0b013e32834d0f1b
复制
发表时间：
2011-12-01
影响因子：
1.6
通讯作者：
Quevedo, Joao
中科院分区：
文献类型：
--
作者：
Moretti, Morgana;Valvassori, Samira S.;Quevedo, Joao
本研究探讨了组蛋白去乙酰化酶抑制剂丁酸钠（SB）对d-苯丙胺（d-AMPH）诱导的躁狂症动物模型大鼠运动行为和脑中线粒体代谢链复合物活性的影响。在逆转治疗中，Wistar大鼠首先用d-AMPH或盐水（Sal）治疗14天。此后，在第8天和第14天之间，向大鼠施用SB或Sal。在预防治疗中，大鼠用SB或Sal治疗14天，并在第8天至第14天之间接受d-AMPH或Sal。d-AMPH治疗增加了Sal-treated大鼠在逆转和预防治疗下的运动行为，SB逆转和预防了d-AMPH相关的活动过度。此外，d-AMPH降低的活动，在盐处理的大鼠在前额叶皮层，海马，纹状体和杏仁核的线粒体线粒体的线粒体复合链复合物在这两个实验中，SB能够扭转和防止这种损害。目前的研究表明，SB的作用机制涉及诱导线粒体功能与行为变化平行，加强了对组蛋白去乙酰化酶抑制剂作为双相情感障碍治疗新药物的可能靶点进行更多研究的必要性。Behavioural Pharmacology 22：766-772（C）2011 Wolters Kluwer Health竖条Lippincott威廉姆斯& Wilkins.
The present study investigated the effect of the histone deacetylase inhibitor, sodium butyrate (SB), on locomotor behavior and on mitochondrial respiratory-chain complexes activity in the brain of rats subjected to an animal model of mania induced by d-amphetamine (d-AMPH). In the reversal treatment, Wistar rats were first treated with d-AMPH or saline (Sal) for 14 days. Thereafter, between days 8 and 14, rats were administered SB or Sal. In the prevention treatment, rats were treated with SB or Sal for 14 days and received d-AMPH or Sal between days 8 and 14. The d-AMPH treatment increased locomotor behavior in Sal-treated rats under reversion and prevention treatment, and SB reversed and prevented d-AMPH-related hyperactivity. Moreover, d-AMPH decreased the activity of mitochondrial respiratory-chain complexes in Sal-treated rats in the prefrontal cortex, hippocampus, striatum, and amygdala in both experiments, and SB was able to reverse and prevent this impairment. The present study suggests that the mechanism of action of SB involves induction of mitochondrial function in parallel with behavioral changes, reinforcing the need for more studies on histone deacetylase inhibitors as a possible target for new medications for bipolar disorder treatment. Behavioural Pharmacology 22:766-772 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.